Research Grade Denintuzumab (DHD10805)

Catalog No.

DHD10805

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Concentration

2.38 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15391

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

SGN-19A, SGN-CD19A, hBU12-491, unconjugated: huBU12, CAS: 1630074-14-4

Clone ID

Denintuzumab

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts, PMID: 31012549

New monoclonal antibodies for the treatment of acute lymphoblastic leukemia, PMID: 27521873

Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia, PMID: 26921100

Emerging antibody-drug conjugates for treating lymphoid malignancies, PMID: 28792782

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies, PMID: 33807678

Document Download

Research Grade Denintuzumab.pdf